litlas
Log inCreate account

Brian I. Rini

Active 2000–2025

292
Papers
68,681
Citations
122
h-index
282
i10-index

Citations

Citations per year for Brian I. Rini1956: 1 citations1997: 1 citations1999: 2 citations2000: 7 citations2001: 8 citations2002: 8 citations2003: 17 citations2004: 21 citations2005: 34 citations2006: 109 citations2007: 180 citations2008: 207 citations2009: 327 citations2010: 345 citations2011: 361 citations2012: 342 citations2013: 410 citations2014: 364 citations2015: 400 citations2016: 450 citations2017: 425 citations2018: 539 citations2019: 2,257 citations2020: 3,394 citations2021: 3,374 citations2022: 2,650 citations2023: 1,780 citations2024: 2,591 citations2025: 1,111 citations2026: 15 citations1957–1996: no citations, so these years are not shown1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,878 citing papers, 25.2% of this breakdownChina: 2,755 citing papers, 14.2% of this breakdownItaly: 1,115 citing papers, 5.8% of this breakdownUnited Kingdom: 1,089 citing papers, 5.6% of this breakdownFrance: 996 citing papers, 5.2% of this breakdownGermany: 794 citing papers, 4.1% of this breakdownCanada: 705 citing papers, 3.6% of this breakdownJapan: 670 citing papers, 3.5% of this breakdownSpain: 602 citing papers, 3.1% of this breakdownNetherlands: 463 citing papers, 2.4% of this breakdownAustralia: 408 citing papers, 2.1% of this breakdownSouth Korea: 334 citing papers, 1.7% of this breakdown
0%25.2%Other 23.5%

Institutions

Fields

  • Medicine67%
  • Biochemistry, Genetics and Molecular Biology20.6%
  • Immunology and Microbiology8.9%
  • Engineering0.7%
  • Neuroscience0.5%
  • Computer Science0.5%
  • Other1.8%

Topics

  • Cancer Immunotherapy and Biomarkers10.7%
  • Renal cell carcinoma treatment8.9%
  • Immunotherapy and Immune Responses3.3%
  • Ferroptosis and cancer prognosis3.2%
  • Immune cells in cancer2.8%
  • Cancer, Hypoxia, and Metabolism2.7%
  • Other68.4%

Coauthors

All papers

Open in search
  1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 cited by 4,643

  2. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Authors: Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, Rustem Gafanov, Robert D. Hawkins, Dmitry Nosov, Frédéric Pouliot, B. Yа. Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Anna Kryzhanivska, Igor Bondarenko, Sérgio Jobim Azevedo, Delphine Borchiellini, Cezary Szczylik, Maurice Markus, Raymond S. McDermott, Jens Bedke, Sophie Tartas, Yen‐Hwa Chang, Satoshi Tamada, Qiong Shou, Rodolfo F. Perini, Mei Chen, Michael B. Atkins, Thomas Powles - New England Journal of Medicine 2019 cited by 3,402

  3. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Négrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, B. Yа. Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K. Choueiri - New England Journal of Medicine 2019 cited by 2,550

  4. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    Authors: David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles - Nature Medicine 2018 cited by 1,250

  5. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

    Authors: Robert J. Motzer, Romain Banchereau, Habib Hamidi, Thomas Powles, David F. McDermott, Michael B. Atkins, Bernard Escudier, Lifen Liu, Ning Leng, Alexander R. Abbas, Jinzhen Fan, Hartmut Koeppen, Jennifer Lin, Susheela Carroll, Kenji Hashimoto, Sanjeev Mariathasan, Marjorie Green, Darren Tayama, Priti S. Hegde, Christina Schiff, Mahrukh Huseni, Brian I. Rini - Cancer Cell 2020 cited by 561

  6. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages

    Authors: Aleksandar Obradović, Nivedita Chowdhury, Scott M. Haake, Casey R. Ager, Vinson Wang, Lukas Vlahos, Xinzheng V. Guo, David H. Aggen, W. Kimryn Rathmell, Eric Jonasch, Joyce E. Johnson, Marc Roth, Kathryn E. Beckermann, Brian I. Rini, James McKiernan, Andrea Califano, Charles G. Drake - Cell 2021 cited by 381

  7. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Authors: Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, Cristina Suárez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Jae‐Lyun Lee, Robert D. Hawkins, Alain Ravaud, B. Yа. Alekseev, Michael Staehler, Motohide Uemura, Ugo De Giorgi, Begoña Mellado, Camillo Porta, Bohuslav Melichar, Howard Gurney, Jens Bedke, Toni K. Choueiri, Francis Parnis, Tarik Khaznadar, Alpa Thobhani, Shi Li, Elisabeth Piault‐Louis, Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C. Green, Robert J. Motzer - The Lancet 2019 cited by 1,010

  8. Renal cell carcinoma

    Authors: Brian I. Rini, Steven C. Campbell, Bernard Escudier - The Lancet 2009 cited by 1,633

  9. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

    Authors: Thomas Powles, Elizabeth R. Plimack, Denis Soulières, Tom Waddell, V.P. Stus, Rustem Gafanov, Dmitry Nosov, Frédéric Pouliot, Bohuslav Melichar, Ihor Vynnychenko, Sérgio Jobim Azevedo, Delphine Borchiellini, Raymond S McDermott, Jens Bedke, Satoshi Tamada, Lina Yin, Mei Chen, L. Rhoda Molife, Michael B. Atkins, Brian I. Rini - The Lancet Oncology 2020 cited by 745

  10. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism

    Authors: Weinan Du, Luchang Zhang, Adina Brett-Morris, Brittany Aguila, János Kerner, Charles L. Hoppel, Michelle Puchowicz, Dolors Serra, Laura Herrero, Brian I. Rini, Steven C. Campbell, Scott M. Welford - Nature Communications 2017 cited by 483

  11. Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Authors: Robert J. Motzer, David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Howard Gurney, Christian Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, M. Brent McHenry, Chung‐Wei Lee, Jennifer L. McCarthy, Flavia Ejzykowicz, Nizar M. Tannir - Cancer 2022 cited by 263

  12. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Authors: Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Mark Warren, Ali Golshayan, Chakshu Sahi, Bernhard J. Eigl, Joseph D. Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J. Knox, Kim N., Christian Kollmannsberger, David F. McDermott, William Oh, Michael B. Atkins, Ronald M. Bukowski, Brian I. Rini, Toni K. Choueiri - Journal of Clinical Oncology 2009 cited by 2,130

  13. Treatment of renal cell carcinoma: Current status and future directions

    Authors: Pedro C. Barata, Brian I. Rini - CA A Cancer Journal for Clinicians 2017 cited by 898

  14. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

    Authors: Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian Kollmannsberger, Howard Gurney, Marc‐Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Toni K. Choueiri, Shruti Shally Saggi, M. Brent McHenry, Robert J. Motzer - ESMO Open 2020 cited by 522

  15. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Authors: Robert J. Motzer, Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S. Tykodi, Philippe Barthélémy, Raya Leibowitz‐Amit, Elizabeth R. Plimack, Sjoukje F. Oosting, Bruce G. Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K. Choueiri, Frede Donskov, Marc‐Oliver Grimm, Howard Gurney, Daniel Y.C. Heng, Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 cited by 780

  16. The immunology of renal cell carcinoma

    Authors: C. Marcela Díaz‐Montero, Brian I. Rini, James H. Finke - Nature Reviews Nephrology 2020 cited by 483

  17. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Authors: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae‐Lyun Lee, Daniel Y.C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N. Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E. Hutson, Sumanta K. Pal, Robert J. Motzer - The Lancet Oncology 2016 cited by 939

  18. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

    Authors: Sumanta K. Pal, Robert G. Uzzo, José A. Karam, Viraj A. Master, Frede Donskov, Cristina Suárez, Laurence Albigès, Brian I. Rini, Yoshihiko Tomita, Ariel Galapo Kann, Giuseppe Procopio, Francesco Massari, Matthew R. Zibelman, I. Antonyan, Mahrukh Huseni, Debasmita Basu, Bo Ci, William Leung, Omara Khan, Sarita Dubey, Axel Bex - The Lancet 2022 cited by 230

  19. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Authors: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Paul N. Mainwaring, Brian I. Rini, Frede Donskov, Hans J. Hammers, Thomas E. Hutson, Jae‐Lyun Lee, Katriina Peltola, Bruce J. Roth, Georg A. Bjarnason, Lajos Géczi, Bhumsuk Keam, Pablo Maroto, Daniel Y.C. Heng, Manuela Schmidinger, Philip W. Kantoff, Anne E. Borgman-Hagey, Colin Hessel, Christian Scheffold, Gisela Schwab, Nizar M. Tannir, Robert J. Motzer - New England Journal of Medicine 2015 cited by 1,226

  20. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

    Authors: Kevin D. Courtney, Jeffrey R. Infante, Elaine T. Lam, Robert A. Figlin, Brian I. Rini, James Brugarolas, Naseem J. Zojwalla, Ann M. Lowe, Keshi Wang, Eli M. Wallace, John A. Josey, Toni K. Choueiri - Journal of Clinical Oncology 2017 cited by 390

  21. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

    Authors: Toni K. Choueiri, Robert J. Motzer, Brian I. Rini, John B.A.G. Haanen, Matthew T. Campbell, B. Venugopal, Christian Kollmannsberger, Gwénaëlle Gravis, Mamoru Uemura, J.L. Lee, Marc‐Oliver Grimm, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Sumanta K. Pal, J. Wang, Mariangela Mariani, S. Krishnaswami, Paul Cislo, A. Chudnovsky, Camilla Fowst, Bo Huang, Alessandra di Pietro, Laurence Albigès - Annals of Oncology 2020 cited by 461

  22. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Authors: Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Lauren C. Harshman, Georg A. Bjarnason, Ulka N. Vaishampayan, Mary J. MacKenzie, Lori Wood, Frede Donskov, Min-Han Tan, Sun Young Rha, Neeraj Agarwal, Christian Kollmannsberger, Brian I. Rini, Toni K. Choueiri - The Lancet Oncology 2013 cited by 1,029

  23. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

    Authors: Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol, Rebecca S. Heist, Toni K. Choueiri, Saby George, Brett Hughes, Matthew D. Hellmann, Dale R. Shepard, Brian I. Rini, Shivaani Kummar, Amy Weise, Matthew J. Riese, Ben Markman, Leisha A. Emens, Daruka Mahadevan, Jason J. Luke, Ginna G. Laport, Joshua Brody, Leonel F. Hernandez‐Aya, Philip Bonomi, Jonathan W. Goldman, Lyudmyla Berim, Daniel J. Renouf, Rachel Goodwin, Brian Munneke, Po Y. Ho, Jessica Hsieh, Ian McCaffery, Long Kwei, Stephen B. Willingham, Richard A. Miller - Cancer Discovery 2019 cited by 339

  24. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

    Authors: Nizar M. Tannir, Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Sangeeth M. George, Frede Donskov, Michael B. Atkins, Howard Gurney, C.K. Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, Ruowei Jiang, Heshani Desilva, В. Э. Федоров, Chung‐Wei Lee, Robert J. Motzer - Annals of Oncology 2024 cited by 192